FDA Panel Supports Avastin For Brain Cancer
SOUTH SAN FRANCISCO (AP) – Federal cancer experts say preliminary studies of a blockbuster Genentech drug are strong enough to speed up its approval for patients with a deadly form of brain cancer.The company has asked the Food and Drug Administration to approve its blockbuster drug Avastin to treat the most dangerous kind of brain tumor. The drug is already approved for patients with lung, breast and colon cancer.
The FDA’s panel of outside cancer experts unanimously said preliminary results in brain cancer patients warrant accelerated approval for the drug. That designation gives market access based on promising early results.
FDA is not required to follow the advice of its panel, though it often does.
South San Francisco-based Genentech is now owned by Swiss drugmaker Roche.
© 2009 The Associated Press. |